What Are Semaglutides? Breaking Down the Buzzword

Wondering what semaglutides are? Get a simple breakdown of the medications, how they work, and how Eden connects you to licensed providers for evaluation.

Key takeaways
  • “Semaglutides” is an informal way people refer to medications that contain the active ingredient semaglutide.
  • Semaglutide is a GLP-1 receptor agonist used to help manage type 2 diabetes and chronic weight management.
  • Brand-name medications that contain semaglutide include Ozempic®, Wegovy®, and Rybelsus®.
  • Semaglutide medications are only available by prescription and must be evaluated by a licensed provider.

This content is for informational purposes only and does not constitute medical advice. Semaglutide is only prescribed when clinically appropriate and is dispensed through state-licensed pharmacies. Eden is not a pharmacy or a healthcare provider. Eden connects individuals with licensed providers for evaluation and care coordination.

The word “semaglutides” seems to be everywhere; in headlines, wellness forums, and even on social media. But what exactly are semaglutides? Are they all the same thing, or just part of a bigger trend in metabolic health?

In this article, we’ll clarify what the term “semaglutides” really refers to, why it’s gained traction in the health and wellness space, and how Eden helps you connect with independent, licensed providers to determine whether a semaglutide-based treatment may be clinically appropriate for your needs.

Is GLP-1 Treatments right for you?

Is GLP-1 Treatments right for you?

Get started

What Does “Semaglutides” Mean?

The term “semaglutides” is not a medical term; it’s a popular shorthand used to refer to medications that contain the active compound semaglutide. These include:

  • Ozempic® – Approved for type 2 diabetes (weekly injection)
  • Wegovy® – Approved for chronic weight management (weekly injection)
  • Rybelsus® – Approved for type 2 diabetes (daily oral tablet)

All three medications contain semaglutide but differ in indication, dose, and delivery method.

What Is Semaglutide?

Semaglutide is part of a class of medications known as GLP-1 receptor agonists. It works by mimicking a naturally occurring hormone (GLP-1) that affects several key metabolic functions, including:

  • Blood sugar regulation
  • Insulin production
  • Appetite control and satiety
  • Digestion speed

Semaglutide was first introduced in the U.S. in 2017 and has since become one of the most widely prescribed medications in its class, especially as awareness of metabolic health continues to grow.

{{primary-cta}}

Why Are People Talking About Semaglutides?

The growing conversation around “semaglutides” can be attributed to:

  • Clinical trial results suggesting significant benefits when combined with nutrition and lifestyle changes*
  • Media attention highlighting celebrity use and weight-related outcomes
  • Digital platforms making access to GLP-1 medications more convenient

But it’s important to keep in mind that semaglutide medications are prescription-only, and they’re not appropriate for everyone. A licensed provider must evaluate your full medical history to determine clinical eligibility.

*The STEP 2 trial used FDA-approved semaglutide (Ozempic®), a once-weekly injectable formulation manufactured by Novo Nordisk and approved for the treatment of type 2 diabetes.

Pills vs Injections: Are All Semaglutides the Same?

No, while they share the same active ingredient, formulations of semaglutide differ in several ways:

Feature Ozempic® Wegovy® Rybelsus®
Route of Administration Weekly injection Weekly injection Daily oral tablet
FDA Indication Type 2 diabetes Chronic weight management Type 2 diabetes
Starting Dose 0.25 mg/week 0.25 mg/week 3 mg/day
Maintenance Dose 2 mg/week (Ozempic) 2.4 mg/week (Wegovy) 7–14 mg/day (Rybelsus)

A provider will recommend the appropriate format based on your health history, diagnosis, and personal preferences.

{{primary-cta}}

Are There Long-Term Side Effects?

Like any medication, semaglutide may come with potential side effects. The most commonly reported include:

  • Nausea
  • Fatigue
  • Digestive discomfort (bloating, diarrhea, or constipation)
  • Appetite suppression

Clinical trials suggest that these symptoms often occur during dose escalation and may improve over time. For long-term use, providers typically monitor lab values, weight trends, and side effect tolerance. The GLP-1 formulation used in the referenced study is the same active ingredient as in FDA-approved Wegovy® for chronic weight management.

How Eden Can Help

Eden is a digital health platform that supports access to care in metabolic health, skincare, and haircare. Eden does not manufacture medications, write prescriptions, or operate as a pharmacy.

Instead, Eden:

  • Connects you with independent, licensed healthcare providers
  • Facilitates safe and secure evaluation and follow-up care
  • Coordinates prescription fulfillment through state-licensed pharmacies
  • Supports you with education and access to clinical guidance throughout your care journey

Whether you're curious about pills or injections, Eden helps you explore semaglutide options with a qualified provider who can assess your needs.

Conclusion

“Semaglutides” might be a buzzword, but what really matters is understanding the medical science and clinical guidance behind the trend. Whether prescribed as Ozempic®, Wegovy®, or Rybelsus®, semaglutide-based treatments are not one-size-fits-all.

If you're wondering whether a semaglutide option may be appropriate for your health goals, the first step is to speak with a licensed provider.

Ready to explore your options? Eden makes it easy to connect with a provider for safe, informed care.

Disclaimer: The FDA does not approve compounded medications for safety, quality, or manufacturing. Prescriptions and a medical evaluation are required for certain products. The information provided on this blog is for general informational purposes only. It is not intended as a substitute for professional advice from a qualified healthcare professional and should not be relied upon as personal health advice. The information contained in this blog is not meant to diagnose, treat, cure, or prevent any disease. Readers are advised to consult with a qualified healthcare professional for any medical concerns, including side effects. Use of this blog's information is at your own risk. The blog owner is not responsible for any adverse effects or consequences resulting from the use of any suggestions or information provided in this blog.

Eden is not a medical provider or a pharmacy. Eden connects individuals with independent licensed healthcare providers who independently evaluate each patient to determine whether a prescription treatment program is appropriate. All prescriptions are written at the sole discretion of the licensed provider. Medications are filled by independent, state-licensed pharmacies. Eden does not manufacture, own, or dispense any medications. Please consult a licensed healthcare provider before making any medical decisions.

Frequently asked questions

GLP-1 Treatments
Personalized doctor-led plans
As low as $276/mo*
Get started
Important safety information
Verified Customer
"I had an incredible experience, and the support that Eden provides is 10/10"
Kerstin
Verified Customer
“I had so many questions in the beginning, and both the doctor and customer support were so patient and thorough.”
Lane L.

Is GLP-1 Treatments right for you?

Is GLP-1 Treatments right for you?

Get started

References

Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., & Lingvay, I. (2021). Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet, 397(10278), 971–984. https://doi.org/10.1016/s0140-6736(21)00213-0

Wilding, J. P., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., & Kushner, R. F. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/nejmoa2032183